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Idiopathic pulmonary fibrosis (IPF) is a progressive diffuse interstitial lung disease with poor
prognosis of unknown etiology that leading ultimately to death. Predisposing factors are
thought to have environmental and genetic inputs.
Objective: We investigated the relationship between HLA-A, B gene polymorphism and idio-
pathic pulmonary fibrosis (IPF) in a Han Chinese population.
Patients and methods: The gene frequency of 36 patients with IPF was detected using a PCR-
SSP grouping method. These values were compared with those a Bone Marrow Bank (Shanghai,
China) of healthy subjects of identical racial origin as the patient group.
Results: The gene frequency of HLA-A*3 (3.5%), HLA-B*14 (1.4%), -B*15 (10.2%), and -B*40
(5.0%)of the IPF group increased significantly (Pc < 0.05) compared with that in the control
group HLA-A*3 (1.0%), HLA-B*14 (0.1%) and -B*15 (1.1%) and -B*40 (0.8%). Investigation of
the link between the HLA-A and -B gene showed the gene frequency of HLA-A2B15 to be
5.0% as well as -A2B40 (4.3%), -A11B15 (5.0%), -A24B48 (2.8%) and -A30B40 (2.8%), which were
significantly higher than those of the control group (Pc < 0.05).
Conclusion: These data suggest that the gene frequency of HLA-A*3, HLA-B*14, -B*15, -B*40,
and the linked gene frequency of HLA-A2B15, -A2B40, -A11B15, -A24B58, -A30B40 is associated
with IPF pathogenesis.
ª 2012 Elsevier Ltd. All rights reserved.510 85351886, 13003329213; fax: þ86 0510 85350777.
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Idiopathic pulmonary fibrosis due to HLA-A and HLA-B gene polymorphism 1457Introduction using t test, there is no difference between IPF and controlIdiopathic pulmonary fibrosis (IPF) is a chronic progressive
and usually lethal disease. It has the pathological features
of fibroblast/myofibroblast proliferation and tissue remod-
eling.1 Predisposing factors are thought to have environ-
mental and genetic inputs. Polymorphisms of genes
encoding for cytokines have been studied in IPF but results
have shown weak association.2e8Interestingly, few studies
were performed on the possible role of human leukocyte
antigen (HLA), which concentrated in about 1978 and show
contradictory results.9e12However,with the increasing
number of this rare disease, and the applications of PCR
technology, we have to face back to this question.Patients and methods
The study protocol was approved by the Ethics Committee
of Nanjing Medical University (Wuxi, China). All subjects
provided written informed consent to be included in the
study.
Patients
Thirty-six lung transplantation recipients from southern
China (24 males, 12 females, 63.4  5.1 years) (Table 1)
diagnosed as IPF was supported by history, physical exam-
ination, HRCT according to guidelines set by the American
Thoracic Society and European Respiratory Society were
the study population.13,14 These 36 end-stage pulmonary
fibrosis patients required continuous high-flow oxygen
inhalation, and unable to complete pulmonary function
tests. They had typical UIP pattern in HRCT. All the patients
underwent total pneumonectomy, and pathological anal-
yses indicated UIP.
A total of 11,955 healthy Han subjects (8129 men and
3826 women, age 48.3  12.1) from the Chinese Bone
Marrow Bank (Shanghai, China) were the control group
because they were of an identical racial origin as the
patient group.5 Healthy volunteers were selected by
Chinese Bone Marrow Bank according to heart lung liver and
kidney function, chest radiographic examination, also
exclude known hereditary and autoimmune diseases. ByTable 1 Demographic clinical physiologic characteristics
of the IPF patients and control group.
Variable IPF (n Z 36) Control
(n Z 11,955)
p
Age 63.4  5.1 48.3  12.1 >0.05
Sex (male/female) 24/12 8129/3826 >0.05
Duration of symptoms
before diagnosis
18.4  15.2
Clubbing (Yes/No) 25/11
Edema (Yes/No) 22/14
Velcro (Yes/No) 34/2
Cellulity (Yes/No) 35/1
PaO2 mmHg 45  12
PAP mmHg 62  38group on the age and sex (p > 0.05, Table 1).
Experimental methods
Peripheral blood (3e5 mL) was extracted and an anticoag-
ulant added. Genomic DNA was extracted using a DNA
Extraction Kit (Sangon Biological Engineering Technology,
Shanghai, China). The concentration and purity of the DNA
was measured by an ultraviolet spectrophotometer. HLA-A,
HLA-B and HLA-DR genotypes were detected using poly-
merase chain reaction-sequence specific primers (PCR-SSP)
using a Biotest Genotyping Regent Kit (Berlin, Germany).
The specific products of PCR then underwent electropho-
resis in 2% agarose gel (150 V, 50 mA) for 4e5 min. After
imaging with UV spectrophotometer software, the HLA
genotype of each sample was obtained.
Statistical analyses
We wanted to calculate the allelotype frequency. We also
used the following formulas:
Phenotype frequency (PF) Z number of masculine
genotypes/number of studied samples.
Gene frequency ðGFÞZ1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 PF
p
We then evaluated if the GF distribution of the control
group adhered to the HardyeWeinberg law. Differences
between the patient group and control group were calcu-
lated using SAS (version 8) statistical software (SAS, Cary,
NC, USA), The GF of HLA alleles were compared using the
chi-square test or the two-tailed Fisher’s exact probability
test. The level of significance was taken as P < 0.05. For
allelic comparisons, Bonferroni’s method was used for
correction of multiple comparisons, multiplying the value
of P obtained in the statistical test by the total number of
alleles tested (corrected P, Pc). The relative risk (RR) was
calculated using the Woolf formula.
Results
Using the chi-square test, results showed that the GF of the
control group adhered to the HardyeWeinberg law.
The gene frequency HLA-A*03, -B*14, -B*15, -B*40 of the
IPF group was significantly different to the GF seen in the
control group (Tables 2 and 3). Among the IPF group, the
linked GF was significantly different compared with that in
the control group. The GF of HLA-A2B15, -A2B40, -A11B15,
-A24B58 and -A30B40 showed a sharp increase (Table 4).
Validation of the findings
Another independent set of 31 patients and 11,955 controls
were used to validate our previous findings. The results of
the HLA genotype and control group are shown in Tables
5e7 Pc values of HLA-A*03, -B*15, -B*40 between two
groups were 0.0143, <0.0023, <0.0023, respectively and Pc
values of linked gene HLA-A2B15, -A2B40, -A11B15, -A24B58
between two groups were 0.006, <0.002, <0.002, <0.002,
respectively. And all others are negative. These results
Table 2 Haplotype frequency of HLA-A in IPF patients and
control subjects.
HLA-A IPF (2nZ 72) Control
(2n Z 23,910)
P Pc RR
Positive
(n)
GF
(%)
Positive
(n)
GF (%)
A *01 1 0.7 531 1.1 1.0000 ns 0.6275
A *02 25 19.2 6307 14.1 0.1047 ns 1.3207
A *03a 12 3.5 460 1.0 0.0020 0.024 3.6217
A *11 11 8.0 4655 11.1 0.3766 ns 0.7874
A *24 12 8.7 3702 8.0 0.7721 ns 1.0800
A *26 2 1.4 620 1.3 0.7101 ns 1.0748
A *29 1 0.7 149 0.3 0.3630 ns 2.2362
A *30 3 2.1 1422 3.0 0.8005 ns 0.7029
A *31 3 2.1 843 1.8 0.7418 ns 1.1857
A *33 7 5.0 2097 4.5 0.7686 ns 1.1122
A *40 1 0.7 0 0 e e e
A *48 1 0.7 0 0 e e e
ns: not significant.
a Significant values of (Pc < 0.05).
1458 J. Zhang et al.further confirmed that gene frequency of HLA-A*03, -B*15,
-B*40, and the linked gene HLA-A2B15, -A2B40, -A11B15,
-A24B58 are significant rise compared to control group, and
has correlation to the IPF pathogenesis.
Discussion
Idiopathic pulmonary fibrosis (IPF) is a fatal progressive
diffuse interstitial lung disease of unknown etiology. ThisTable 3 Haplotype frequency of HLA-B in IPF patients and con
HLA-B IPF (2n Z 72) Control (2n Z
Positive (n) GF (%) Positive (n)
B *08 3 2.1 174
B *13 7 5.0 2343
B *14a 2 1.4 32
B *15a 14 10.2 532
B *18 1 0.7 61
B *27 3 2.1 687
B *35 2 1.4 1110
B *38 2 1.4 600
B *40a 7 5.0 369
B *41 1 0.7 0
B *44 3 2.1 530
B *46 4 2.8 2591
B *48 2 1.4 338
B *50 1 0.7 10
B *51 7 5.0 1342
B *52 3 2.1 498
B *54 3 2.1 596
B *55 2 1.4 560
B *57 1 0.7 538
B *58 4 2.8 1197
ns: not significant.
a Significant values of (Pc < 0.05).disease is characterized by the formation of fibroblast foci
that contain activated myofibroblasts. However, there was
no further research of underlying genetic mechanisms.15e17
Lederer performed a retrospective cohort study of 2635
patients with IPF listed for lung transplantation between
1995 and 2003 at 94 transplant centers in the United States.
They found that black and Hispanic patients with IPF have
worse survival than whites. And infered that different
progression of IPF due to different ethnic and heritage
backgrounds.18
Studies on gene polymorphisms and susceptibility to IPF
have been mostly focused on genes related to cytokine
pathways and most results have been negative or have
shown a weak association .2,3,19e24
Interestingly, few studies regarding the possible role of
HLA in susceptibility are very old and concentrated in about
1978.9e12HLA typing technology based on serological
methods by then.20 years later with the development of
molecular biology techniques, it improves the accuracy and
practicability of HLA typing. On the other hand, with the
accumulation of the rare diseases, American Thoracic
Society/European Respiratory Society (ATS/ERS) published
a consensus of IPF diagnosis and treatment in 2000. After 11
years of IPF clinical and laboratory research, the first
evidence-based IPF diagnosis and treatment guidelines to
be available in 2011. So at this time we do need to re-face
and review this issue.
HLA is the most abundant polymorphism in the human
body. HLA class I molecules comprise the classical HLA-A,
-B, and -C antigens which are expressed on the surface of
most mammalian cells.25,26 The HLA class II subtypes HLA-
DR, DQ and DP regulate T cell dependent immune
responses and are expressed by specific cell types,trol subjects.
23,910) P Pc RR
GF (%)
0.4 0.0976 ns 5.7447
5.0 0.9899 ns 0.9954
0.1 <0.0001 <0.002 20.8247
1.1 <0.0001 <0.002 8.7683
0.1 0.1698 ns 5.4622
1.4 0.4638 ns 1.4550
2.3 0.7748 ns 0.6003
1.3 0.7018 ns 1.1106
0.8 <0.0001 <0.002 6.3208
0 e e e
1.1 0.2140 ns 1.8860
5.6 0.1520 ns 0.5143
0.7 0.2707 ns 1.9715
0 0.0324 ns 33.3194
2.8 0.1237 ns 1.7380
1.0 0.1894 ns 2.0072
1.3 0.2665 ns 1.6772
1.2 0.6858 ns 1.1900
1.1 1.0000 ns 0.6193
2.5 0.7831 ns 1.1134
Table 4 Linked gene frequency of HLA-AB in IPF patients and control subjects.
HLA-A-B IPF (2n Z 72) Control (2n Z 23,910) P Pc RR
Positive (n) GF (%) Positive (n) GF (%)
A2B8 1 0.7 34 0 0.0996 ns 9.7998
A2B13 3 2.1 712 0.7 0.4752 ns 1.4039
A2B15a 7 5.0 438 0.5 <0.0001 <0.002 5.3250
A2B27 1 0.7 268 0.3 0.5554 ns 1.2432
A2B35 5 3.5 722 0.8 0.0666 ns 2.3074
A2B40a 6 4.3 224 0.2 <0.0001 <0.002 8.9249
A2B46 5 3.5 610 0.6 0.0370 ns 2.7311
A2B51 5 3.5 552 0.6 0.0257 ns 3.0181
A2B55 2 1.4 302 0.3 0.2308 ns 2.2066
A3B35 2 1.4 138 0.1 0.0660 ns 4.8289
A11B13 2 1.4 864 0.9 1.0000 ns 0.7713
A11B15a 7 5.0 276 0.3 <0.0001 <0.002 8.4506
A11B27 2 1.4 182 0.2 0.1051 ns 3.6615
A11B54 3 2.1 236 0.2 0.0350 ns 4.2355
A24B27 3 2.1 158 0.2 0.0125 ns 6.3265
A24B40 2 1.4 206 0.2 0.1286 ns 3.2349
A24B58a 4 2.8 40 0 <0.0001 <0.002 33.3194
A30B13 2 1.4 2280 2.4 0.0518 ns 0.2922
A30B40a 4 2.8 34 0.04 <0.0001 <0.002 39.1993
A33B58 3 2.1 1012 1.1 1.0000 ns 0.9877
ns: not significant.
a Significant values of (Pc < 0.05).
Idiopathic pulmonary fibrosis due to HLA-A and HLA-B gene polymorphism 1459primarily on antigen processing cells such as dendritic cells
and macrophages,although they can be expressed on
fibroblasts. HLA is associated with degenerative, autoim-
mune and communicable diseases in humans. IPF is strongly
associated with the immune response.
Does the HLA genotype associate with IPF? We investi-
gated the relationship between the gene polymorphism of
HLA and prevalence of IPF in a Han population from
southern China to explore the cause and the pathogenesis
of IPF. We found that, in comparison with the control
group, the haplotype frequency of HLA-A*03, -B*14, -B*15,
and -B*40, was significantly different (Pc < 0.05). In the
linked gene of HLA-A, B, the GF of HLA-A2B15, -A2B40,
-A11B15, -A30B40, and -A24B58 was significantly elevatedTable 5 Haplotype frequency of HLA-A in IPF patients and con
HLA-A IPF (2n Z 62) Control (2n Z 2
Positive (n) GF (%) Positive (n)
A *01 2 1.4 531
A *02 15 11.0 6307
A *03a 6 4.3 460
A *11 14 10.2 4655
A *24 8 5.7 3702
A *26 2 1.4 620
A *30 4 2.8 1422
A *31 3 2.1 843
A *33 6 4.3 2097
A *69 1 0.7 49
A *74 1 0.7 12
ns: not significant.
a Significant values of (Pc < 0.05).in comparison with that of the control (Pc < 0.05). The
other GF values showed negative outcomes.
In order to verify this results, another independent set of
31 patients were used to validate our findings. The results
of gene frequency are similar with previous study: the
frequency of HLA-A03, B15, B40, but except B14 signifi-
cantly increased in IPF group. The linked GF of A2B15,
A2B40, A11B15, A24B58 except A30B40 also showed a sharp
increase. The two experiments are consistent on HLA-A03,
B15, B40, A2B15, A2B40, A11B15, A24B58. So we conclude
that HLA-A03, B15, B40, and linked gene HLA-A2B15,
A2B40, A11B15, A24B58 relevant to the incidence of the
IPF of Chinese han IPF patients. And the related HLA may
take role in IPF pathogenesis.trol subjects.
3,910) P Pc RR
GF (%)
1.1 0.4008 ns 1.0114
14.1 0.709 ns 1.1354
1.0 0.0013 0.0143 4.2811
11.1 05276 ns 0.9615
8.0 0.582 ns 0.9672
1.3 0.6756 ns 1.1550
3.0 0.7857 ns 0.8813
1.8 0.4813 ns 1.2743
4.5 0.7944 ns 1.1099
0.1 0.1212 ns 3.6537
0 0.033 ns 14.9192
Table 6 Haplotype frequency of HLA-B in IPF patients and control subjects.
HLA-B IPF (2n Z 62) Control (2n Z 23,910) P Pc RR
Positive (n) GF (%) Positive (n) GF (%)
B *07 2 1.4 430 0.9 1.0000 ns 1.5497
B *12 1 0.7 22 0 0.0577 ns 15.1452
B *13 1 0.7 2343 5.0 0.0306 ns 0.1422
B *15a 6 4.3 532 1.1 <0.0001 <0.0023 3.7578
B *27 4 2.8 687 1.4 0.1026 ns 1.9399
B *35 5 3.5 1110 2.3 0.212 ns 1.5009
B *37 1 0.7 150 0.3 0.3236 ns 2.2213
B *38 1 0.7 600 1.3 1.0000 ns 0.5553
B *40a 9 6.5 369 0.8 <0.0001 <0.0023 8.1267
B *44 2 1.4 530 1.1 0.3998 ns 1.2574
B *46 3 2.1 2591 5.6 0.1307 ns 0.3858
B *48 2 1.4 338 0.7 0.2185 ns 1.9716
B *51 2 1.4 1342 2.8 1.0000 ns 0.4966
B *52 2 1.4 498 1.0 0.3704 ns 1.3381
B *53 1 0.7 41 0.1 0.1028 ns 8.1267
B *54 2 1.4 596 1.3 0.2006 ns 1,1181
B *55 3 2.1 560 1.2 0.1772 ns 1.7850
B *56 1 0.7 83 0.2 0.1952 ns 4.0144
B *58 5 3.5 1197 2.5 0.1303 ns 1.3918
B *60 5 3.5 2172 4.6 0.7863 ns 0.7670
B *62 2 1.4 1517 3.2 0.4369 ns 0.4393
B *67 1 0.7 136 0.3 0.2986 ns 2.4500
B *75 1 0.7 818 1.7 0.7254 ns 0.4073
ns: not significant.
a Significant values of (Pc < 0.05).
Table 7 Linked gene frequency of HLA-AB in IPF patients and control subjects.
HLA-A-B IPF (2n Z 62) Control (2n Z 23,910) P Pc RR
Positive (n) GF (%) Positive (n) GF (%)
A2B8 1 0.7 34 0 0.0864 ns 9.7998
A2B13 2 1.4 712 0.7 0.7071 ns 0.9359
A2B15a 5 3.5 438 0.5 0.0003 0.006 3.8036
A2B27 1 0.7 268 0.3 0.5025 ns 1.2433
A2B35 3 2.1 722 0.8 0.4368 ns 1.3845
A2B40a 6 4.3 224 0.2 <0.0001 <0.002 8.9249
A2B46 3 2.1 610 0.6 0.2100 ns 1.6387
A2B51 4 2.8 552 0.6 0.0552 ns 2.4145
A2B55 1 0.7 302 0.3 0.5448 ns 1.1032
A3B35 1 0.7 138 0.1 0.3022 ns 2.4145
A11B13 2 1.4 864 0.9 1.0000 ns 0.7713
A11B15a 5 3.5 276 0.3 <0.0001 <0.002 6.0361
A11B27 2 1.4 182 0.2 0.0187 ns 3.6615
A11B54 2 1.4 236 0.2 0.1256 ns 2.8237
A24B27 2 1.4 158 0.2 0.0642 ns 4.2176
A24B40 2 1.4 206 0.2 0.1005 ns 3.2349
A24B58a 3 2.1 40 0 <0.0001 <0.002 24.9896
A30B13 0 0 2280 2.4 e ee e
A30B40 2 1.4 34 0.04 0.0039 0.078 19.5997
A33B58 2 1.4 1012 1.1 1.0000 ns 0.6585
ns: not significant.
a Significant values of (Pc < 0.05).
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Idiopathic pulmonary fibrosis due to HLA-A and HLA-B gene polymorphism 1461Varpela reported that high prevalences of HLA-B15 in
patients with cryptogenic fibrosing alveolitis in 1979.11 And
in 1983 Libby12 reported an increase frequency of HLA-A03
was observed in Caucasian IPF patients. Although we study
the patients from different ethnic origin, these two results
coincide with our findings.
Since then after 20 years silence, a reported from
Mexico included 75 IPF was published in 2005. 41% of the
patients diagnosis was confirmed by morphology (open lung
biopsy) based on typical microscopic findings of usual
interstitial pneumonia. The genotype of HLA-B15, B52 and
B35 were significantly associated with increased risk to IPF.
It is very interesting that this is the third study to show HLA-
B15 has potential link with IPF prevalence. Therefore, we
hypothesized that HLA-B15 has some necessary linkage with
the pathogenesis of IPF, which requires further experi-
mental verification.
We speculated that the two results are not completely
consistent is due to the limited number of our research
groups. This is one of the limitation of our study. IPF is
a rare disease, the incidence is 7e10 per 100 000 per
year.27So it took us 10 years to collect the 67 patients who
underwent lung transplantation in IPF recipients. And the
most advantage of this research is all the cases are typical
end-stage IPF patients who suffered resection of lung, and
the pathology showed typical UIP pattern. Another limita-
tion of this study is the study population is limited to the
southern Han Chinese people, so the conclusion may not be
applied to other ethnic and regional population. Further
study by using a larger sample is required. Even so, the
results contribute to further research in etiology and
pathology of IPF and play instructive role in exploration of
the disease in other countries.
In summary, our results suggest a role for a genetic
susceptibility associated to HLA in IPF, especially one
particular haplotype, HLA-B*15. The present study could
open up the new research directions for exploring the
pathogenesis and pathology of IPF.
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